JP2007507494A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007507494A5 JP2007507494A5 JP2006532235A JP2006532235A JP2007507494A5 JP 2007507494 A5 JP2007507494 A5 JP 2007507494A5 JP 2006532235 A JP2006532235 A JP 2006532235A JP 2006532235 A JP2006532235 A JP 2006532235A JP 2007507494 A5 JP2007507494 A5 JP 2007507494A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- optionally
- alkyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 230000008485 antagonism Effects 0.000 claims 2
- 230000009286 beneficial effect Effects 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- -1 optionally Chemical group 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 108010024114 Complement 3b Receptors Proteins 0.000 claims 1
- 102000015612 Complement 3b Receptors Human genes 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 239000007800 oxidant agent Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0302667A SE0302667D0 (sv) | 2003-10-07 | 2003-10-07 | Novel Compounds |
| SE0302666A SE0302666D0 (sv) | 2003-10-07 | 2003-10-07 | Novel Compounds |
| PCT/SE2004/001421 WO2005033115A1 (en) | 2003-10-07 | 2004-10-05 | New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007507494A JP2007507494A (ja) | 2007-03-29 |
| JP2007507494A5 true JP2007507494A5 (en:Method) | 2007-11-22 |
Family
ID=34425473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006532235A Pending JP2007507494A (ja) | 2003-10-07 | 2004-10-05 | ケモカイン受容体アンタゴニストとりわけＣＸ３ＣＲ１として有用な新規な２−置換４−アミノ−チアゾロ［４，５−ｄ］ピリミジン |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20070142386A1 (en:Method) |
| EP (1) | EP1675862A1 (en:Method) |
| JP (1) | JP2007507494A (en:Method) |
| KR (1) | KR20060120014A (en:Method) |
| AU (1) | AU2004278276B2 (en:Method) |
| BR (1) | BRPI0415050A (en:Method) |
| CA (1) | CA2541533A1 (en:Method) |
| IL (1) | IL174508A0 (en:Method) |
| MX (1) | MXPA06003792A (en:Method) |
| NO (1) | NO20062061L (en:Method) |
| WO (1) | WO2005033115A1 (en:Method) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9903544D0 (sv) | 1999-10-01 | 1999-10-01 | Astra Pharma Prod | Novel compounds |
| GB2359551A (en) | 2000-02-23 | 2001-08-29 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
| GB0221828D0 (en) | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
| GB0328243D0 (en) | 2003-12-05 | 2004-01-07 | Astrazeneca Ab | Methods |
| US8518401B1 (en) | 2004-10-29 | 2013-08-27 | Eisai R&D Management Co., Ltd. | Treating inflammatory diseases with antibodies that inhibit fractalkine-CXCR1 interaction |
| US20090239882A1 (en) * | 2004-12-17 | 2009-09-24 | Astrazeneca Ab | Thiazolopyramidine Compounds for the Modulation of Chemokine Receptor Activity |
| AR053347A1 (es) * | 2005-04-06 | 2007-05-02 | Astrazeneca Ab | Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos |
| UA90707C2 (en) * | 2005-04-06 | 2010-05-25 | Астразенека Аб | Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives |
| PE20080145A1 (es) | 2006-03-21 | 2008-02-11 | Janssen Pharmaceutica Nv | Tetrahidro-pirimidoazepinas como moduladores de trpv1 |
| WO2008005303A2 (en) * | 2006-06-30 | 2008-01-10 | Janssen Pharmaceutica N.V. | Thiazolopyrimidine modulators of trpv1 |
| TW200820973A (en) * | 2006-09-29 | 2008-05-16 | Astrazeneca Ab | Novel compounds 480 |
| RU2437889C2 (ru) | 2006-09-29 | 2011-12-27 | Астразенека Аб | НОВЫЕ 5,7-ДИЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ [1,3]ТИАЗОЛО[4,5-d]ПИРИМИДИН-2-(3Н)-АМИНА И ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ |
| PE20091102A1 (es) | 2007-12-17 | 2009-07-25 | Janssen Pharmaceutica Nv | Moduladores imidazolo-, oxazolo-, y tiazolopirimidina del trpv1 |
| WO2009079000A1 (en) * | 2007-12-17 | 2009-06-25 | Janssen Pharmaceutica N.V. | Imidazolopyrimidine modulators of trpv1 |
| DK2262777T3 (en) | 2008-03-07 | 2016-05-17 | Acraf | 1-benzyl-3-hydroxymetylindazolderivater and their use in the treatment of diseases based on the expression of MCP-1 and CX3CR1 |
| PL2254870T3 (pl) * | 2008-03-07 | 2016-07-29 | Acraf | Pochodne 1-benzylo-3-hydroksymetyloindazolu i ich zastosowanie w leczeniu chorób opartych na ekspresji MCP-1, CX3CR1 |
| EA018976B1 (ru) | 2008-03-07 | 2013-12-30 | Ацьенде Кимике Рьюните Анджелини Франческо А.К.Р.А.Ф. С.П.А. | Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии мср-1, cx3cr1 и p40 |
| JO3437B1 (ar) | 2009-10-30 | 2019-10-20 | Esai R & D Man Co Ltd | أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها |
| EP2648754A4 (en) * | 2010-12-07 | 2016-02-24 | Philadelphia Health & Educatio | METHOD OF INHIBITING CANCER METASTASES |
| TWI543975B (zh) * | 2011-09-13 | 2016-08-01 | Eisai R&D Man Co Ltd | Pyrrolidin-3-yl acetic acid derivatives |
| US8476301B2 (en) | 2011-09-13 | 2013-07-02 | Eisai R&D Management Co., Ltd. | Pyrrolidin-3-ylacetic acid derivative |
| CA2900926A1 (en) * | 2013-03-12 | 2014-09-18 | Eisai R&D Management Co., Ltd. | Salt of pyrrolidin-3-yl acetic acid derivative and crystals thereof |
| WO2014142086A1 (ja) * | 2013-03-13 | 2014-09-18 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピロリジン－３－イル酢酸誘導体およびピペリジン－３－イル酢酸誘導体 |
| WO2018204370A1 (en) | 2017-05-02 | 2018-11-08 | Drexel University | Cx3cr1 small molecule antagonists, and methods using same |
| GB201811169D0 (en) * | 2018-07-06 | 2018-08-29 | Kancera Ab | New compounds |
| CR20250196A (es) | 2022-10-19 | 2025-11-21 | Astrazeneca Ab | 1,3,5-triazinas 2,4,6-trisustituidas como moduladores de cx3cr1 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9802729D0 (sv) * | 1998-08-13 | 1998-08-13 | Astra Pharma Prod | Novel Compounds |
| SE9903544D0 (sv) * | 1999-10-01 | 1999-10-01 | Astra Pharma Prod | Novel compounds |
| SE0101082D0 (sv) * | 2001-03-27 | 2001-03-27 | Astrazeneca Ab | Novel use |
| SE0101322D0 (sv) * | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | Novel compounds |
-
2004
- 2004-10-05 KR KR1020067006638A patent/KR20060120014A/ko not_active Withdrawn
- 2004-10-05 EP EP04775512A patent/EP1675862A1/en not_active Withdrawn
- 2004-10-05 AU AU2004278276A patent/AU2004278276B2/en not_active Ceased
- 2004-10-05 JP JP2006532235A patent/JP2007507494A/ja active Pending
- 2004-10-05 CA CA002541533A patent/CA2541533A1/en not_active Abandoned
- 2004-10-05 MX MXPA06003792A patent/MXPA06003792A/es unknown
- 2004-10-05 WO PCT/SE2004/001421 patent/WO2005033115A1/en not_active Ceased
- 2004-10-05 BR BRPI0415050-3A patent/BRPI0415050A/pt not_active IP Right Cessation
- 2004-10-05 US US10/575,534 patent/US20070142386A1/en not_active Abandoned
-
2006
- 2006-03-23 IL IL174508A patent/IL174508A0/en unknown
- 2006-05-08 NO NO20062061A patent/NO20062061L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007507494A5 (en:Method) | ||
| RU2007101653A (ru) | Производные 1-азабицикло[3.3.1]нонанов | |
| JP2004514663A5 (en:Method) | ||
| JP2006507220A5 (en:Method) | ||
| JP2009504763A5 (en:Method) | ||
| BR0317294A (pt) | Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase quinase-3 e de prevenção e/ou tratamento de doenças, e, uso dos intermediários | |
| RU2004104625A (ru) | Аналоги простагландинов в качестве агонистов рецептора ep4 | |
| RU2006112428A (ru) | Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение | |
| RU2007142328A (ru) | Производные тиоксантина в качестве ингибиторов миелопероксидазы | |
| JP2008526999A5 (en:Method) | ||
| JP2008509187A5 (en:Method) | ||
| RU2004132856A (ru) | Фармацевтический препарат с модифицированным высвобождением | |
| JP2008521827A5 (en:Method) | ||
| JP2007515447A5 (en:Method) | ||
| JP2015535247A5 (en:Method) | ||
| JP2006503850A5 (en:Method) | ||
| RU99101081A (ru) | Режим введения ингибиторов н+, к+-атфазы | |
| JP2005526696A5 (en:Method) | ||
| JP2008534453A5 (en:Method) | ||
| NO20050569L (no) | Fremgangsmate for behandling av alvorlig hjertesvikt og medikament for dette | |
| JP2009541387A5 (en:Method) | ||
| RU2004133387A (ru) | Фармацевтический препарат с немедленным высвобождением | |
| RU2002101622A (ru) | Нафтохиноновые производные и их использование для лечения и борьбы с туберкулезом | |
| EA019037B1 (ru) | 5-[5-[2-[3,5-бис(трифторметил)фенил-2-метилпропаноилметиламино]-4-(4-фтор-2-метилфенил)]-2-пиридинил]-2-алкилпролинамиды в качестве антагонистов рецептора nk1 | |
| JP2004525178A5 (en:Method) |